Low‐dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter

Low‐dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter

Background The first‐line therapy is effective for the treatment of primary immune thrombocytopenia (ITP); however, maintaining the long‐term responses remains challenging. Low‐dose decitabine (DAC) has been adopted to treat refractory ITP, while its role in macrophage polarization has not been full...

Full description

Bibliographic Details
Main Authors: Xia Shao, Pengcheng Xu, Lili Ji, Boting Wu, Yanxia Zhan, Xibing Zhuang, Yang Ou, Fanli Hua, Lihua Sun, Feng Li, Xiangdong Wang, Hao Chen, Yunfeng Cheng
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Clinical and Translational Medicine
Subjects:
decitabine
krüppel‐like factor 4
m2 macrophages
peroxisome proliferator‐activated receptor‐γ
primary immune thrombocytopenia
Online Access:https://doi.org/10.1002/ctm2.1344

Internet

https://doi.org/10.1002/ctm2.1344

Similar Items